Travere Therapeutics Inc. (TVTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
State of Incorp. CA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments306,814347,214427,939356,572271,930311,348
Cash and cash equivalents58,17661,688165,75384,77262,436102,873
Short-term investments248,638285,526262,186271,800209,494208,475
Receivables25,77918,54616,16133,06718,04814,490
Inventory, net of allowances, customer advances and progress billings9,4106,9227,3137,6086,0825,619
Inventory9,4106,9227,3137,6086,0825,619
Prepaid expense     1,3951,716
Other undisclosed current assets274,772113,755131,41413,160131,609162,505
Total current assets:616,775486,437582,827410,407429,064495,678
Noncurrent Assets
Inventory, Noncurrent31,494     
Operating lease, right-of-use asset18,06121,00023,196  
Property, plant and equipment7,4799,04911,1069,4182,8913,146
Long-term investments and receivables      15,000
Long-term investments      15,000
Intangible assets, net (including goodwill)104,443145,038148,435154,125158,136187,627
Goodwill    936936936
Intangible assets, net (excluding goodwill)104,443145,038148,435153,189157,200186,691
Other noncurrent assets10,66111,06111,06933,48914,7097,709
Total noncurrent assets:172,138186,148193,806197,032175,736213,482
TOTAL ASSETS:788,913672,585776,633607,439604,800709,160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities160,666113,03290,32468,92678,35956,649
Accounts payable41,67517,29015,14412,13326,6146,954
Accrued liabilities118,99195,74275,18056,79351,74549,695
Deferred revenue7,09611,97616,268  
Debt    2,61322,457
Business combination, contingent consideration, liability  7,0007,400   
Other liabilities5,2375,7226,1886,3348,5904,065
Other undisclosed current liabilities4,9094,4333,90817,4005,88721,450
Total current liabilities:177,908142,163124,08892,66095,449104,621
Noncurrent Liabilities
Long-term debt and lease obligation377,263375,545258,078243,675212,255195,091
Long-term debt, excluding current maturities377,263375,545226,581215,339204,861195,091
Liabilities, other than long-term debt32,932112,02692,35540,52720,8944,496
Deferred revenue 1,83510,93120,379  
Other liabilities8,4859,38512,27640,52720,8944,496
Operating lease, liability22,61227,51031,49728,3367,394
Business combination, contingent consideration, liability  64,20059,700   
Other undisclosed noncurrent liabilities    19,36455,00686,699
Total noncurrent liabilities:410,195487,571350,433303,566288,155286,286
Total liabilities:588,103629,734474,521396,226383,604390,907
Equity
Equity, attributable to parent200,81042,851302,112211,213221,196318,253
Common stock766544
Additional paid in capital1,327,8811,059,9751,068,634797,985636,910589,795
Accumulated other comprehensive income (loss)(1,456)(2,907)(562)(902)726(1,529)
Accumulated deficit(1,125,622)(1,014,223)(765,966)(585,875)(416,444)(270,017)
Total equity:200,81042,851302,112211,213221,196318,253
TOTAL LIABILITIES AND EQUITY:788,913672,585776,633607,439604,800709,160

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues145,238212,018227,490198,321175,338164,246
Cost of revenue(11,450)(219,914)(29,044)(9,781)(5,234)(5,527)
Cost of goods and services sold(11,450)(7,592)(6,784)(6,126)(5,234)(5,527)
Gross profit:133,788(7,896)198,446188,540170,104158,719
Operating expenses(521,926)(258,670)(360,211)(364,703)(310,414)(244,286)
Other undisclosed operating income     2,9495,527
Operating loss:(388,138)(266,566)(161,765)(176,163)(137,361)(80,040)
Nonoperating income (expense)12,028(11,603)(17,917)(12,627)(9,087)(21,827)
Investment income, nonoperating21,7686,2761,9935,00310,055 
Other nonoperating income (expense)1,5949742311,420(314)(474)
Interest and debt expense(3,400)(11,300)(20,100)(19,050)(18,828)(17,042)
Loss from continuing operations before equity method investments, income taxes:(379,510)(289,469)(199,782)(207,840)(165,276)(118,909)
Other undisclosed income from continuing operations before income taxes3,40011,30020,10019,05018,82817,042
Loss from continuing operations before income taxes:(376,110)(278,169)(179,682)(188,790)(146,448)(101,867)
Income tax expense (benefit)(223)(313)(409)19,35921(811)
Loss from continuing operations:(376,333)(278,482)(180,091)(169,431)(146,427)(102,678)
Loss before gain (loss) on sale of properties:(180,091)(169,431)(146,427)(102,678)
Net loss:(376,333)(278,482)(180,091)(169,431)(146,427)(102,678)
Other undisclosed net income (loss) attributable to parent264,934     
Net loss available to common stockholders, diluted:(111,399)(278,482)(180,091)(169,431)(146,427)(102,678)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(376,333)(278,482)(180,091)(169,431)(146,427)(102,678)
Comprehensive loss:(376,333)(278,482)(180,091)(169,431)(146,427)(102,678)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent266,385(2,345)340(1,628)2,255(514)
Comprehensive loss, net of tax, attributable to parent:(109,948)(280,827)(179,751)(171,059)(144,172)(103,192)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: